Scientific news

Discover OPM’s posters!

ESMO 2025:

• REVERT study: a phase Ib/IIa study to assess the efficacy of the first-in-class RIPK2 inhibitor OPM-101 in patients with advanced melanoma resistant to anti-PD-1-based regimens

Authors : MICHIELIN Olivier, MD Hôpitaux Universitaires de Genève; Bruno ROBIN, Pharm.D. ; Maria Eugenia RIVEIRO, PhD ; Jan HOFLACK, PhD ; Philippe GENNE, PhD Oncodesign Precision Medicine

UEG Week 2024:

• Unveiling the strong safety profile and high target engagement of opm-101, a first-in-class orally available ripk2 inhibitor, in a phase 1 clinical trial in healthy volunteers​​

Authors : L Peyrin-Biroulet, M.D., PhD IHU INFINY – CHRU de NANCY, France; B. Robin Pharm.D, J. Hoflack, PhD, P. Genne, PhD – Oncodesign Precision Medicine, Dijon, France​

AACR 2024:

• “Unlocking the Potential of OPM-383: A Novel LRRK2 Inhibitor in Cancer Therapy”
  Authors: Maria Eugenia Riveiro, Petra Blom, Kenji Shoji, Jan Hoflack
  Oncodesign Precision Medicine S.A., Dijon, France
• “OPM-116, a highly potent and specific PI3Kγ inhibitor to enhance antitumor immunity”
  Authors: Kenji F. Shoji, Oleksandr Levenets, Petra Blom, Maria Eugenia Riveiro, Jan Hoflack
  Oncodesign Precision Medicine S.A., Dijon, France

IBD 2024 :

• “Unveiling the strong safety profile and high target engagement of OPM-101, a first-in-class orally available RIPK2 Inhibitor, in healthy volunteers, a Phase 1 Clinical trial “
  Authors: ROBIN Bruno, Pharm.D. – HOFLACK Jan, PhD. – GENNE Philippe, PhD.
  Oncodesign Precision Medicine S.A., Dijon, France

[News] Discover the April 2, 2025 interview with Karine Lignel on the Journal des Biotechs!

An opportunity to review OPM’s development strategy and the latest news linked to the submission of the protocol for its Phase 1b/2a REVERT clinical trial with OPM-101!

To find out more, click here

Webinaire 1 April 05.30pm (in french)

Discover the replay here !